TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02234427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 2-week aspirin therapy (81mg/day)
Study: NCT01080911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: spinal morphine 0.05 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
Study: NCT01861730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Study: NCT05564156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention groups
Description: The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
Study: NCT02811965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow Condition 1
Description: The heel is offloaded by placing the heel on a standard hospital pillow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow Condition 2
Description: The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
Study: NCT02180425

Intervention type: DRUG
Intervention: Tretinoin or Adapalene
Description: Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.

Intervention type: DRUG
Intervention: Isotretinoin
Description: Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
Study: NCT02811965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel Foam Pillow
Description: An economy heel offloading device constructed of egg shell foam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading Device A
Description: Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
Study: NCT01861730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Study: NCT04639570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KneuroKnits
Description: The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
Study: NCT02829229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based obesity treatment (PP)
Description: Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
Study: NCT02504463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan IV
Description: Single IV administration
Study: NCT04355416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin Oral gel
Description: application of curcumin oral gel after scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subgingival scaling and root planing
Description: subgingival scaling and root planing without application of curcumin gel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: subgingival scaling and root planing
Description: subgingival scaling and root planing without application of curcumin gel
Study: NCT00456092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Capsules for oral administration
Study: NCT02504463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c]-Samidorphan sublingual
Description: Single sublingual administration containing radiolabel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c]-Samidorphan oral
Description: Single oral administration containing radiolabel
Study: NCT00456092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study: NCT05621421

Intervention type: PROCEDURE
Intervention: FFR and IVUS guided PCI
Description: PCI to the long lesion guided with FFR and IVUS
Study: NCT03930901

Intervention type: OTHER
Group type: OTHER
Intervention: Health education learning package
Description: Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
Study: NCT04243655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA 330-II
Description: One unit for 2-4 hours treatment, for 3 consecutive days
Study: NCT02379949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
Study: NCT04243655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment (SMT)
Description: SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment (SMT)
Description: SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
Study: NCT03803514

Intervention type: DRUG
Intervention: Recombinant EPO
Description: Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
Study: NCT03278483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 mg Oral Tablet
Description: Isoniazid tablets 300mg daily plus pyridoxine 50mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin 600 mg Oral Tablet
Description: Rifampin capsules 600mg daily
Study: NCT03868917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block using pressure measurement technique
Description: The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
Study: NCT00986609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-1 peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 peptide-poly-ICLC adjuvant vaccine
Description: Receive adjuvant vaccination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT01382680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidewire
Description: Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidewire
Description: Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
Study: NCT02843529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altoida: neuropsychological, MRI, EEG and CSF biomarkers
Description: Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altoida: neuropsychological, MRI, EEG and CSF biomarkers
Description: Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects.
Study: NCT03029559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Loading
Description: Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Loading
Description: Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent Hypoxia
Description: Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Intermittent Hypoxia
Description: Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
Study: NCT02379949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Group Therapy
Description: Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
Study: NCT00283725

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
Study: NCT00068055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omr-lgG-am
Description: Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polygam® S/D
Description: Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline.
Study: NCT02451826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: CVR delivering Ulipristal acetate and one tablet levonorgestrel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal acetate
Description: CVR delivering Ulipristal acetate and one tablet levonorgestrel.
Study: NCT04662346

Intervention type: OTHER
Group type: OTHER
Intervention: Difficulty score system for robotic pancreatoduodenectomy
Description: calculate the score for patient in you cohort
Study: NCT02472665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasma-derived FVIII/VWF concentrate
Description: 1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
Study: NCT02100592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation treatment on Erigo Hocoma
Description: 5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation treatment on Erigo Hocoma
Description: Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
Study: NCT01565993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemoclip
Description: A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Polipectomy
Description: Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
Study: NCT01960231

Intervention type: OTHER
Intervention: OGTT
Study: NCT00003545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Study: NCT06503835

Intervention type: PROCEDURE
Intervention: Fluoroscopy Guided Transforaminal Epidural Ozone Injection
Description: All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.

Intervention type: PROCEDURE
Intervention: Fluoroscopy Guided Transforaminal Epidural Steroid Injection
Description: All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level

Intervention type: PROCEDURE
Intervention: Fluoroscopy Guided Transforaminal Epidural Steroid Injection
Description: All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
Study: NCT03323905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony MRI guided High Intensity Focused Ultrasound (HIFU)
Description: The use of the MRI-HIFU for the ablation of leiomyomas
Study: NCT01824303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS 400 mg
Description: LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LiRIS Placebo
Description: LiRIS Placebo contains lactose, inactive substance.
Study: NCT02100267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride (SK-1211)
Description: Subjects received saline and 0.039-25 mg/mL of Methacholine chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride (SK-1211)
Description: Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
Study: NCT03614013

Intervention type: OTHER
Intervention: Immunotherapy responders/non-responders
Description: paraffin samples will be collected retrospectively along with clinical data